Name of first foreign vaccine against coronavirus became known

The first foreign coronavirus vaccine, close to the stage of mass production, may be called Covuity. This became known to the British edition of The Telegraph, which studied applications for registration of trademarks in the United States and the European Union.

The application for registration of the drug Covuity was submitted to the EU regulators on May 30. It describes the drug as a “vaccine for human use”. The application was approved in early November.

In the United States, a similar application was filed on June 1, but has not yet been approved and is still being considered. In addition, the domain name is registered by the drug development companies Pfizer and BioNTech.

The publication also provides other possible names for: Rnaxcovi, Kovimerna and Comirnaty. However, their final approval is less likely.

It is noted that companies are responsible for choosing a name, since in the context of a global pandemic it can become a household name and be used by any manufacturers around the world – by analogy with aspirin.

Reports of successful vaccine trials from Pfizer and BioNTech have boosted stock markets in many countries, most notably the United States. At the same time, the best results, in addition to the drug developers, were shown by the shares of companies considered undervalued.